New combo therapy targets tough blood cancers
NCT ID NCT06291987
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a combination of two drugs, ivosidenib and ruxolitinib, in people with advanced blood cancers (MPNs) that have an IDH1 mutation. The main goal is to find the safest dose and see if the combo helps control the disease. About 18 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could cousins be as good as siblings for stem cell donation?
- New drug cocktail targets deadliest blood cancers
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- New oral drug could tame overactive bone marrow in rare blood cancers
- New pill for rare blood cancers shows promise in early trial
- New pill shows promise for rare blood cancers in early trial